A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Cemiplimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-Lung 1
- Sponsors Regeneron Pharmaceuticals
- 17 Jun 2024 Planned End Date changed from 30 Apr 2024 to 30 Jun 2025.
- 17 Jun 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Jun 2025.
- 24 Oct 2023 Results of exploratory sub group analysis (from studies EMPOWER-Lung 1 and EMPOWER-Lung 3) of pts with squamous NSCLC treated with cemiplimab presented at the 48th European Society for Medical Oncology Congress